301 related articles for article (PubMed ID: 16270435)
1. More flexibility on reporting to federal agencies about injuries to research subjects.
Maloney DM
Hum Res Rep; 2002 Jan; 17(1):1-2. PubMed ID: 16270435
[No Abstract] [Full Text] [Related]
2. NIH tightens up monitoring of gene-therapy mishaps.
Smaglik P
Nature; 2000 Mar; 404(6773):5. PubMed ID: 10716412
[No Abstract] [Full Text] [Related]
3. Making clinical trials safer for human subjects.
Baram M
Am J Law Med; 2001; 27(2-3):253-82. PubMed ID: 11467112
[No Abstract] [Full Text] [Related]
4. Restoring public trust in gene therapy.
Kennedy EM
J Biolaw Bus; 2001; 4(3):3-4. PubMed ID: 12962103
[No Abstract] [Full Text] [Related]
5. NIH under fire over gene-therapy trials..
Wadman M
Nature; 2000 Jan; 403(6767):237. PubMed ID: 10659820
[No Abstract] [Full Text] [Related]
6. Gene therapy investigations proliferate.
Hollon T
Nat Med; 2000 Mar; 6(3):235. PubMed ID: 10700200
[No Abstract] [Full Text] [Related]
7. Adverse events reporting--the tip of an iceberg.
Shamoo AE
Account Res; 2001; 8(3):197-218. PubMed ID: 12481780
[TBL] [Abstract][Full Text] [Related]
8. Gene therapy on trial.
Marshall E
Science; 2000 May; 288(5468):951-7. PubMed ID: 10841710
[No Abstract] [Full Text] [Related]
9. Gene therapy institute denies that errors led to trial death.
Smaglik P
Nature; 2000 Feb; 403(6772):820. PubMed ID: 10733385
[No Abstract] [Full Text] [Related]
10. Tighter watch urged on adenoviral vectors...with proposal to report all 'adverse events'.
Smaglik P
Nature; 1999 Dec; 402(6763):707. PubMed ID: 10617181
[No Abstract] [Full Text] [Related]
11. Light, fast, and flexible: a new approach to regulation of human gene therapy.
Cregan JA
McGeorge Law Rev; 2000; 32(1):261-87. PubMed ID: 15709266
[No Abstract] [Full Text] [Related]
12. Regulating human gene therapy: legislative overreaction to human subject protection failures.
Leavitt WJ
Adm Law Rev; 2001; 53(1):315-41. PubMed ID: 16189905
[No Abstract] [Full Text] [Related]
13. Congress gets tough with gene therapy.
Smaglik P
Nature; 2000 Feb; 403(6770):583-4. PubMed ID: 10688166
[No Abstract] [Full Text] [Related]
14. IRBs, human subjects, and reporting adverse events.
Maloney DM
Hum Res Rep; 2005 Nov; 20(11):3. PubMed ID: 16358480
[No Abstract] [Full Text] [Related]
15. US plans to protect clinical research participants.
Fox JL
Nat Biotechnol; 2000 Jul; 18(7):709. PubMed ID: 10888829
[No Abstract] [Full Text] [Related]
16. Investigation of gene therapy begins.
Fox JL
Nat Biotechnol; 2000 Feb; 18(2):143-4. PubMed ID: 10657112
[No Abstract] [Full Text] [Related]
17. Continued concern: human subject protection, the institutional review board, and continuing review.
Hoffman S
Tenn Law Rev; 2001; 68(4):725-70. PubMed ID: 16189912
[No Abstract] [Full Text] [Related]
18. Safety panel backs principle of gene-therapy trials.
Check E
Nature; 2002 Dec; 420(6916):595. PubMed ID: 12478252
[No Abstract] [Full Text] [Related]
19. FDA halts all gene therapy trials at Penn.
Marshall E
Science; 2000 Jan; 287(5453):565, 567. PubMed ID: 10691531
[No Abstract] [Full Text] [Related]
20. Cancer fears cast doubts on future of gene therapy.
Check E
Nature; 2003 Feb; 421(6924):678. PubMed ID: 12610583
[No Abstract] [Full Text] [Related]
[Next] [New Search]
